Reid Robison
Reid Robison | |
|---|---|
| Born | September 11, 1976 Hinsdale, Illinois, U.S. |
| Alma mater | University of Utah (M.D.) University of Utah (M.B.A.) Brigham Young University (B.S.) |
| Scientific career | |
| Fields | Psychiatry Mental Health Psychedelic Therapy |
| Website | https://www.reidrobison.com/ |
Reid Robison (born September 1976 in Illinois) is an American board-certified psychiatrist known primarily for his work with psychedelic medicines. As an early adopter and researcher of the use of ketamine in psychiatry, Robison has made significant contributions to ketamine-assisted psychotherapy (KAP) and other treatment modalities using ketamine for mental health conditions. He previously served as coordinating investigator for a study on MDMA-assisted psychotherapy for eating disorders, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), and he continues to lead research and psychiatric clinical trials involving psychedelics. To date, Robison has guided thousands of ketamine-assisted therapy sessions and Spravato dosing sessions. He currently serves as Medical Director of Center for Change, an eating disorder treatment center in Utah, and Chief Clinical Officer of Numinus, a Vancouver-based mental health company focused on psychedelic research and treatments. Robison is an adjunct professor at both the University of Utah and Brigham Young University.